カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

ゼルヤンツ(トファチニブ)医薬品の世界市場2022：錠剤、徐放錠

◆英語タイトル：Global Xeljanz (tofacitnib) Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

GlobalInfoResearchが発行した調査報告書（GIR22DC3963）◆商品コード：GIR22DC3963
◆発行会社（リサーチ会社）：GlobalInfoResearch
◆発行日：2023年1月
◆ページ数：78
◆レポート形式：英語 / PDF
◆納品方法：Eメール（注文後2-3日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

世界のゼルヤンツ(トファチニブ)医薬品市場レポートは、グローバル市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
Global Info Research社の最新のリサーチによると、世界のゼルヤンツ(トファチニブ)医薬品の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

ゼルヤンツ(トファチニブ)医薬品市場はタイプとアプリケーションによって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメントは次をカバーします。
・錠剤、徐放錠

アプリケーション別セグメントは次のように区分されます。
・関節リウマチ、乾癬性関節炎、その他

世界のゼルヤンツ(トファチニブ)医薬品市場の主要な市場プレーヤーは以下のとおりです。
・Pfizer

地域別セグメントは次の地域・国をカバーします。
・北米（アメリカ、カナダ、メキシコ）
・欧州（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南米（ブラジル、アルゼンチン、コロンビア）
・中東/アフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査資料の内容は計15章あります。
・第1章では、ゼルヤンツ(トファチニブ)医薬品製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なゼルヤンツ(トファチニブ)医薬品メーカーの企業概要、2019年～2022年までのゼルヤンツ(トファチニブ)医薬品の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なゼルヤンツ(トファチニブ)医薬品メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別ゼルヤンツ(トファチニブ)医薬品の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのゼルヤンツ(トファチニブ)医薬品の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのゼルヤンツ(トファチニブ)医薬品市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびゼルヤンツ(トファチニブ)医薬品の産業チェーンを掲載しています。
・第13、14、15章では、ゼルヤンツ(トファチニブ)医薬品の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
– ゼルヤンツ(トファチニブ)医薬品の概要
– 種類別分析（2017年vs2021年vs2028年）：錠剤、徐放錠
– 用途別分析（2017年vs2021年vs2028年）：関節リウマチ、乾癬性関節炎、その他
– 世界のゼルヤンツ(トファチニブ)医薬品市場規模・予測
– 世界のゼルヤンツ(トファチニブ)医薬品生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Pfizer
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：錠剤、徐放錠
・用途別分析2017年-2028年：関節リウマチ、乾癬性関節炎、その他
・ゼルヤンツ(トファチニブ)医薬品の北米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・ゼルヤンツ(トファチニブ)医薬品のヨーロッパ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・ゼルヤンツ(トファチニブ)医薬品のアジア市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・ゼルヤンツ(トファチニブ)医薬品の南米市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・ゼルヤンツ(トファチニブ)医薬品の中東・アフリカ市場
– 種類別市場規模2017年-2028年
– 用途別市場規模2017年-2028年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

❖ レポートの目次 ❖

1 Market Overview
1.1 Xeljanz (tofacitnib) Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Xeljanz (tofacitnib) Drug Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Tablets
1.2.3 Extended-release Tablets
1.3 Market Analysis by Application
1.3.1 Overview: Global Xeljanz (tofacitnib) Drug Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Rheumatoid Arthritis
1.3.3 Psoriatic Arthritis
1.3.4 Other
1.4 Global Xeljanz (tofacitnib) Drug Market Size & Forecast
1.4.1 Global Xeljanz (tofacitnib) Drug Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Xeljanz (tofacitnib) Drug Sales in Volume (2017-2028)
1.4.3 Global Xeljanz (tofacitnib) Drug Price (2017-2028)
1.5 Global Xeljanz (tofacitnib) Drug Production Capacity Analysis
1.5.1 Global Xeljanz (tofacitnib) Drug Total Production Capacity (2017-2028)
1.5.2 Global Xeljanz (tofacitnib) Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Xeljanz (tofacitnib) Drug Market Drivers
1.6.2 Xeljanz (tofacitnib) Drug Market Restraints
1.6.3 Xeljanz (tofacitnib) Drug Trends Analysis
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Xeljanz (tofacitnib) Drug Product and Services
2.1.4 Pfizer Xeljanz (tofacitnib) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Xeljanz (tofacitnib) Drug Breakdown Data by Manufacturer
3.1 Global Xeljanz (tofacitnib) Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Xeljanz (tofacitnib) Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Xeljanz (tofacitnib) Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Xeljanz (tofacitnib) Drug Manufacturer Market Share in 2021
3.4.2 Top 6 Xeljanz (tofacitnib) Drug Manufacturer Market Share in 2021
3.5 Global Xeljanz (tofacitnib) Drug Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Xeljanz (tofacitnib) Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Xeljanz (tofacitnib) Drug Market Size by Region
4.1.1 Global Xeljanz (tofacitnib) Drug Sales in Volume by Region (2017-2028)
4.1.2 Global Xeljanz (tofacitnib) Drug Revenue by Region (2017-2028)
4.2 North America Xeljanz (tofacitnib) Drug Revenue (2017-2028)
4.3 Europe Xeljanz (tofacitnib) Drug Revenue (2017-2028)
4.4 Asia-Pacific Xeljanz (tofacitnib) Drug Revenue (2017-2028)
4.5 South America Xeljanz (tofacitnib) Drug Revenue (2017-2028)
4.6 Middle East and Africa Xeljanz (tofacitnib) Drug Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Xeljanz (tofacitnib) Drug Sales in Volume by Type (2017-2028)
5.2 Global Xeljanz (tofacitnib) Drug Revenue by Type (2017-2028)
5.3 Global Xeljanz (tofacitnib) Drug Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Xeljanz (tofacitnib) Drug Sales in Volume by Application (2017-2028)
6.2 Global Xeljanz (tofacitnib) Drug Revenue by Application (2017-2028)
6.3 Global Xeljanz (tofacitnib) Drug Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Xeljanz (tofacitnib) Drug Sales by Type (2017-2028)
7.2 North America Xeljanz (tofacitnib) Drug Sales by Application (2017-2028)
7.3 North America Xeljanz (tofacitnib) Drug Market Size by Country
7.3.1 North America Xeljanz (tofacitnib) Drug Sales in Volume by Country (2017-2028)
7.3.2 North America Xeljanz (tofacitnib) Drug Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Xeljanz (tofacitnib) Drug Sales by Type (2017-2028)
8.2 Europe Xeljanz (tofacitnib) Drug Sales by Application (2017-2028)
8.3 Europe Xeljanz (tofacitnib) Drug Market Size by Country
8.3.1 Europe Xeljanz (tofacitnib) Drug Sales in Volume by Country (2017-2028)
8.3.2 Europe Xeljanz (tofacitnib) Drug Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Type (2017-2028)
9.2 Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Application (2017-2028)
9.3 Asia-Pacific Xeljanz (tofacitnib) Drug Market Size by Region
9.3.1 Asia-Pacific Xeljanz (tofacitnib) Drug Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Xeljanz (tofacitnib) Drug Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Xeljanz (tofacitnib) Drug Sales by Type (2017-2028)
10.2 South America Xeljanz (tofacitnib) Drug Sales by Application (2017-2028)
10.3 South America Xeljanz (tofacitnib) Drug Market Size by Country
10.3.1 South America Xeljanz (tofacitnib) Drug Sales in Volume by Country (2017-2028)
10.3.2 South America Xeljanz (tofacitnib) Drug Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Xeljanz (tofacitnib) Drug Sales by Type (2017-2028)
11.2 Middle East & Africa Xeljanz (tofacitnib) Drug Sales by Application (2017-2028)
11.3 Middle East & Africa Xeljanz (tofacitnib) Drug Market Size by Country
11.3.1 Middle East & Africa Xeljanz (tofacitnib) Drug Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Xeljanz (tofacitnib) Drug Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Xeljanz (tofacitnib) Drug and Key Manufacturers
12.2 Manufacturing Costs Percentage of Xeljanz (tofacitnib) Drug
12.3 Xeljanz (tofacitnib) Drug Production Process
12.4 Xeljanz (tofacitnib) Drug Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Xeljanz (tofacitnib) Drug Typical Distributors
13.3 Xeljanz (tofacitnib) Drug Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Xeljanz (tofacitnib) Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Xeljanz (tofacitnib) Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer Xeljanz (tofacitnib) Drug Product and Services
Table 6. Pfizer Xeljanz (tofacitnib) Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Global Xeljanz (tofacitnib) Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 8. Global Xeljanz (tofacitnib) Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 9. Market Position of Manufacturers in Xeljanz (tofacitnib) Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 10. Global Xeljanz (tofacitnib) Drug Production Capacity by Company, (K Units): 2020 VS 2021
Table 11. Head Office and Xeljanz (tofacitnib) Drug Production Site of Key Manufacturer
Table 12. Xeljanz (tofacitnib) Drug New Entrant and Capacity Expansion Plans
Table 13. Xeljanz (tofacitnib) Drug Mergers & Acquisitions in the Past Five Years
Table 14. Global Xeljanz (tofacitnib) Drug Sales by Region (2017-2022) & (K Units)
Table 15. Global Xeljanz (tofacitnib) Drug Sales by Region (2023-2028) & (K Units)
Table 16. Global Xeljanz (tofacitnib) Drug Revenue by Region (2017-2022) & (USD Million)
Table 17. Global Xeljanz (tofacitnib) Drug Revenue by Region (2023-2028) & (USD Million)
Table 18. Global Xeljanz (tofacitnib) Drug Sales by Type (2017-2022) & (K Units)
Table 19. Global Xeljanz (tofacitnib) Drug Sales by Type (2023-2028) & (K Units)
Table 20. Global Xeljanz (tofacitnib) Drug Revenue by Type (2017-2022) & (USD Million)
Table 21. Global Xeljanz (tofacitnib) Drug Revenue by Type (2023-2028) & (USD Million)
Table 22. Global Xeljanz (tofacitnib) Drug Price by Type (2017-2022) & (USD/Unit)
Table 23. Global Xeljanz (tofacitnib) Drug Price by Type (2023-2028) & (USD/Unit)
Table 24. Global Xeljanz (tofacitnib) Drug Sales by Application (2017-2022) & (K Units)
Table 25. Global Xeljanz (tofacitnib) Drug Sales by Application (2023-2028) & (K Units)
Table 26. Global Xeljanz (tofacitnib) Drug Revenue by Application (2017-2022) & (USD Million)
Table 27. Global Xeljanz (tofacitnib) Drug Revenue by Application (2023-2028) & (USD Million)
Table 28. Global Xeljanz (tofacitnib) Drug Price by Application (2017-2022) & (USD/Unit)
Table 29. Global Xeljanz (tofacitnib) Drug Price by Application (2023-2028) & (USD/Unit)
Table 30. North America Xeljanz (tofacitnib) Drug Sales by Country (2017-2022) & (K Units)
Table 31. North America Xeljanz (tofacitnib) Drug Sales by Country (2023-2028) & (K Units)
Table 32. North America Xeljanz (tofacitnib) Drug Revenue by Country (2017-2022) & (USD Million)
Table 33. North America Xeljanz (tofacitnib) Drug Revenue by Country (2023-2028) & (USD Million)
Table 34. North America Xeljanz (tofacitnib) Drug Sales by Type (2017-2022) & (K Units)
Table 35. North America Xeljanz (tofacitnib) Drug Sales by Type (2023-2028) & (K Units)
Table 36. North America Xeljanz (tofacitnib) Drug Sales by Application (2017-2022) & (K Units)
Table 37. North America Xeljanz (tofacitnib) Drug Sales by Application (2023-2028) & (K Units)
Table 38. Europe Xeljanz (tofacitnib) Drug Sales by Country (2017-2022) & (K Units)
Table 39. Europe Xeljanz (tofacitnib) Drug Sales by Country (2023-2028) & (K Units)
Table 40. Europe Xeljanz (tofacitnib) Drug Revenue by Country (2017-2022) & (USD Million)
Table 41. Europe Xeljanz (tofacitnib) Drug Revenue by Country (2023-2028) & (USD Million)
Table 42. Europe Xeljanz (tofacitnib) Drug Sales by Type (2017-2022) & (K Units)
Table 43. Europe Xeljanz (tofacitnib) Drug Sales by Type (2023-2028) & (K Units)
Table 44. Europe Xeljanz (tofacitnib) Drug Sales by Application (2017-2022) & (K Units)
Table 45. Europe Xeljanz (tofacitnib) Drug Sales by Application (2023-2028) & (K Units)
Table 46. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Region (2017-2022) & (K Units)
Table 47. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Region (2023-2028) & (K Units)
Table 48. Asia-Pacific Xeljanz (tofacitnib) Drug Revenue by Region (2017-2022) & (USD Million)
Table 49. Asia-Pacific Xeljanz (tofacitnib) Drug Revenue by Region (2023-2028) & (USD Million)
Table 50. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Type (2017-2022) & (K Units)
Table 51. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Type (2023-2028) & (K Units)
Table 52. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Application (2017-2022) & (K Units)
Table 53. Asia-Pacific Xeljanz (tofacitnib) Drug Sales by Application (2023-2028) & (K Units)
Table 54. South America Xeljanz (tofacitnib) Drug Sales by Country (2017-2022) & (K Units)
Table 55. South America Xeljanz (tofacitnib) Drug Sales by Country (2023-2028) & (K Units)
Table 56. South America Xeljanz (tofacitnib) Drug Revenue by Country (2017-2022) & (USD Million)
Table 57. South America Xeljanz (tofacitnib) Drug Revenue by Country (2023-2028) & (USD Million)
Table 58. South America Xeljanz (tofacitnib) Drug Sales by Type (2017-2022) & (K Units)
Table 59. South America Xeljanz (tofacitnib) Drug Sales by Type (2023-2028) & (K Units)
Table 60. South America Xeljanz (tofacitnib) Drug Sales by Application (2017-2022) & (K Units)
Table 61. South America Xeljanz (tofacitnib) Drug Sales by Application (2023-2028) & (K Units)
Table 62. Middle East & Africa Xeljanz (tofacitnib) Drug Sales by Region (2017-2022) & (K Units)
Table 63. Middle East & Africa Xeljanz (tofacitnib) Drug Sales by Region (2023-2028) & (K Units)
Table 64. Middle East & Africa Xeljanz (tofacitnib) Drug Revenue by Region (2017-2022) & (USD Million)
Table 65. Middle East & Africa Xeljanz (tofacitnib) Drug Revenue by Region (2023-2028) & (USD Million)
Table 66. Middle East & Africa Xeljanz (tofacitnib) Drug Sales by Type (2017-2022) & (K Units)
Table 67. Middle East & Africa Xeljanz (tofacitnib) Drug Sales by Type (2023-2028) & (K Units)
Table 68. Middle East & Africa Xeljanz (tofacitnib) Drug Sales by Application (2017-2022) & (K Units)
Table 69. Middle East & Africa Xeljanz (tofacitnib) Drug Sales by Application (2023-2028) & (K Units)
Table 70. Xeljanz (tofacitnib) Drug Raw Material
Table 71. Key Manufacturers of Xeljanz (tofacitnib) Drug Raw Materials
Table 72. Direct Channel Pros & Cons
Table 73. Indirect Channel Pros & Cons
Table 74. Xeljanz (tofacitnib) Drug Typical Distributors
Table 75. Xeljanz (tofacitnib) Drug Typical Customers
List of Figures
Figure 1. Xeljanz (tofacitnib) Drug Picture
Figure 2. Global Xeljanz (tofacitnib) Drug Revenue Market Share by Type in 2021
Figure 3. Tablets
Figure 4. Extended-release Tablets
Figure 5. Global Xeljanz (tofacitnib) Drug Revenue Market Share by Application in 2021
Figure 6. Rheumatoid Arthritis
Figure 7. Psoriatic Arthritis
Figure 8. Other
Figure 9. Global Xeljanz (tofacitnib) Drug Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 10. Global Xeljanz (tofacitnib) Drug Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Xeljanz (tofacitnib) Drug Sales (2017-2028) & (K Units)
Figure 12. Global Xeljanz (tofacitnib) Drug Price (2017-2028) & (USD/Unit)
Figure 13. Global Xeljanz (tofacitnib) Drug Production Capacity (2017-2028) & (K Units)
Figure 14. Global Xeljanz (tofacitnib) Drug Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Xeljanz (tofacitnib) Drug Market Drivers
Figure 16. Xeljanz (tofacitnib) Drug Market Restraints
Figure 17. Xeljanz (tofacitnib) Drug Market Trends
Figure 18. Global Xeljanz (tofacitnib) Drug Sales Market Share by Manufacturer in 2021
Figure 19. Global Xeljanz (tofacitnib) Drug Revenue Market Share by Manufacturer in 2021
Figure 20. Xeljanz (tofacitnib) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Xeljanz (tofacitnib) Drug Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Xeljanz (tofacitnib) Drug Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Xeljanz (tofacitnib) Drug Sales Market Share by Region (2017-2028)
Figure 24. Global Xeljanz (tofacitnib) Drug Revenue Market Share by Region (2017-2028)
Figure 25. North America Xeljanz (tofacitnib) Drug Revenue (2017-2028) & (USD Million)
Figure 26. Europe Xeljanz (tofacitnib) Drug Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Xeljanz (tofacitnib) Drug Revenue (2017-2028) & (USD Million)
Figure 28. South America Xeljanz (tofacitnib) Drug Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Xeljanz (tofacitnib) Drug Revenue (2017-2028) & (USD Million)
Figure 30. Global Xeljanz (tofacitnib) Drug Sales Market Share by Type (2017-2028)
Figure 31. Global Xeljanz (tofacitnib) Drug Revenue Market Share by Type (2017-2028)
Figure 32. Global Xeljanz (tofacitnib) Drug Price by Type (2017-2028) & (USD/Unit)
Figure 33. Global Xeljanz (tofacitnib) Drug Sales Market Share by Application (2017-2028)
Figure 34. Global Xeljanz (tofacitnib) Drug Revenue Market Share by Application (2017-2028)
Figure 35. Global Xeljanz (tofacitnib) Drug Price by Application (2017-2028) & (USD/Unit)
Figure 36. North America Xeljanz (tofacitnib) Drug Sales Market Share by Type (2017-2028)
Figure 37. North America Xeljanz (tofacitnib) Drug Sales Market Share by Application (2017-2028)
Figure 38. North America Xeljanz (tofacitnib) Drug Sales Market Share by Country (2017-2028)
Figure 39. North America Xeljanz (tofacitnib) Drug Revenue Market Share by Country (2017-2028)
Figure 40. United States Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Xeljanz (tofacitnib) Drug Sales Market Share by Type (2017-2028)
Figure 44. Europe Xeljanz (tofacitnib) Drug Sales Market Share by Application (2017-2028)
Figure 45. Europe Xeljanz (tofacitnib) Drug Sales Market Share by Country (2017-2028)
Figure 46. Europe Xeljanz (tofacitnib) Drug Revenue Market Share by Country (2017-2028)
Figure 47. Germany Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Xeljanz (tofacitnib) Drug Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Xeljanz (tofacitnib) Drug Revenue Market Share by Region (2017-2028)
Figure 56. China Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Xeljanz (tofacitnib) Drug Sales Market Share by Type (2017-2028)
Figure 63. South America Xeljanz (tofacitnib) Drug Sales Market Share by Application (2017-2028)
Figure 64. South America Xeljanz (tofacitnib) Drug Sales Market Share by Country (2017-2028)
Figure 65. South America Xeljanz (tofacitnib) Drug Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Xeljanz (tofacitnib) Drug Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Xeljanz (tofacitnib) Drug Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Xeljanz (tofacitnib) Drug Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Xeljanz (tofacitnib) Drug Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Xeljanz (tofacitnib) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Xeljanz (tofacitnib) Drug in 2021
Figure 77. Manufacturing Process Analysis of Xeljanz (tofacitnib) Drug
Figure 78. Xeljanz (tofacitnib) Drug Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ ゼルヤンツ(トファチニブ)医薬品の世界市場2022：錠剤、徐放錠(Global Xeljanz (tofacitnib) Drug Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • Tysabri（ナタリズマブ）医薬品の世界市場2022：多発性硬化症、クローン病
  • 肺動脈性肺高血圧症（PAH）医薬品の世界市場2022：カルシウム拮抗薬、新規標的治療薬、その他
  • ソリリス医薬品の世界市場2022：血漿交換、血漿注入

    • ◆H&Iグローバルリサーチのお客様（例）◆